![Colin Walsh](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Colin Walsh
Direktor/Vorstandsmitglied bei Locki Therapeutics Ltd.
Profil
Colin Walsh currently works at Locki Therapeutics Ltd., as Director from 2021.
Aktive Positionen von Colin Walsh
Unternehmen | Position | Beginn |
---|---|---|
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Direktor/Vorstandsmitglied | 04.11.2021 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Health Technology |